Biotech & pharma
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Media Release
Oct 25 · 11:00GlobeNewswire
2,114 press releases in English indexed under biotech & pharma.
Media Release
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma
The Economic Community of West African States (ECOWAS) Commission, in collaboration with the Centre for Research and Information on Substance Abuse (CRISA), has convened the 16th Biennial International Conference on Drugs, Alcohol and Society in Africa to strengthen evidence-based responses to substance use across West Africa. Held from the 21st to 22nd of October 2026 in Abuja, Nigeria, the conference is themed “Substance Use Research and Data Systems in Africa: Advances, Relevance and Challenges.” It brings together researchers, policymakers, public health professionals and development partners to examine emerging drug trends, strengthen data systems and develop practical recommendations for prevention, treatment and rehabilitation. Delivering a statement on behalf of the ECOWAS Commissioner for Human Development and Social Affairs, Prof. Nassirou Bako-Arifari, Dr. Daniel Amankwaah, Head of the ECOWAS Drug Prevention and Control Division, highlighted the growing public health and security challenges associated with substance use and illicit drug trafficking. He disclosed that, as of September 2026, 12 drug treatment and rehabilitation centres in 10 Member States had received renovation and equipment upgrades, while more than 300 health and allied professionals had been trained in evidence-based prevention and treatment. He also highlighted ECOWAS efforts to advance Alternatives to Incarceration, promoting treatment, rehabilitation and social reintegration for eligible people who use drugs and come into contact with the criminal justice system. He reaffirmed the Commission’s commitment to strengthening regional data through the West African Epidemiology Network on Drug Use (WENDU). Representing CRISA, Prof. Gboyega Abikoye expressed satisfaction with the Centre’s achievements after more than 30 years, highlighting its work in substance use research, information sharing on alcohol use and abuse, and the organisation of workshops and conferences to advance knowledge and inform responses to drug-related challenges. In remarks delivered on behalf of the UNODC Country Representative in Nigeria, Cheikh Touré, by Dr. Akanidomo Ibanga, Project Management Support Specialist at UNODC, participants were urged to bridge the gap between research and policymaking. He emphasised that evidence must inform government decisions, resource allocation, prevention programmes and access to quality treatment and care. The conference features country-level drug situation reports, panel discussions and research presentations, including a study on alternatives to incarceration for people who use drugs in Nigeria. Through its partnership with CRISA and other stakeholders, ECOWAS continues to promote regional cooperation and evidence-informed policies for more effective and humane responses to substance use across West Africa. Distributed by APO Group on behalf of Economic Community of West African States (ECOWAS).
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression on or after immunotherapy plus chemotherapy An early median progression-free survival of 6.9 months was observed Significant unmet need remains for patients who have progressed on an … Continue reading "BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy"
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor … Continue reading "Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer"
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) … Continue reading "NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma"
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL … Continue reading "Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors"
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027 200 mg and 600 mg doses have been generally well-tolerated Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting … Continue reading "Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026"
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...